Global Public Health Partnering Deal Trends, Players and Financials Report 2010-2016

Feb 08, 2016, 08:10 ET from Research and Markets

DUBLIN, Feb. 8, 2016 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/rg3895/global_public) has announced the addition of the "Global Public Health Partnering 2010-2016: Deal trends, players and financials" company profile to their offering.

Global Public Health Partnering 2010 to 2016 provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Global Public Health Partnering 2010 to 2016 includes:

  • Trends in Public Health dealmaking in the biopharma industry since 2010
  • Analysis of Public Health deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Public Health deal contract documents
  • Comprehensive access to over 3500 Public Health deal records
  • The leading Public Health deals by value since 2010
  • Most active Public Health dealmakers since 2010

In Global Public Health Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

For more information visit http://www.researchandmarkets.com/research/rg3895/global_public

Media Contact:

Laura Wood , +353-1-481-1716, press@researchandmarkets.net

 

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com